# The Heart Failure Collaboratory Public-Private Partnership Between the United States Food and Drug Administration, the Inova Heart and Vascular Institute, and the Heart Failure Community

> **NIH FDA R18** · INOVA HEALTH CARE SERVICES · 2020 · $149,005

## Abstract

The Heart Failure Collaboratory (HFC) is a public-private partnership between the Inova Heart and
Vascular Institute (IHVI), the United States Food and Drug Administration (FDA), and the major
stakeholders in the heart failure (HF) community, including patients, clinical investigators, academic
leaders, pharmaceutical and device industry representatives, society representatives, third party
payers, and government representatives from the United States National Institutes of Health (NIH)
and Centers for Medicare and Medicaid Services (CMS). The HFC aims to advance scientific
discussion, efficiency of clinical trials and evidence generation for HF, and foster development of
therapies; to achieve these goals the HFC creates a collaborative environment in which FDA,
government agencies including NIH and CMS, and the HF community can interact to optimize
innovation and advancement of new therapeutic products. This proposal describes how the HFC
executive committee, led by the program chair and principal investigator, in coordination with the HFC
working groups, will continue to discuss and develop solutions to identified obstacles within the HF
ecosystem. These include but are not limited to refining clinical trial endpoint definitions, facilitating
standardized data collection and analyses, streamlining clinical trial performance by utilizing novel
digital and automatic mechanisms, establishing systems to reward individuals, organizations, and
networks with shared goals and dedication to advancing HF treatment, nurturing inclusion of patients
and particularly those of diverse populations in all aspects of clinical research, and developing new
diverse clinical research leaders and investigators. This application outlines the organizational
infrastructure and support to be provided as the HFC strides into the future to overcome barriers to
the development and implementation of new therapeutic interventions for patients with HF. It builds
upon the initial successes of the public-private partnership between the FDA and IHVI administering
the HFC, and further boosts the impact of the HFC to enhance clinical trial efficiency, therapeutic
development, and patient wellbeing.

## Key facts

- **NIH application ID:** 10087166
- **Project number:** 1R18FD006920-01
- **Recipient organization:** INOVA HEALTH CARE SERVICES
- **Principal Investigator:** CHRISTOPHER M O'CONNOR
- **Activity code:** R18 (R01, R21, SBIR, etc.)
- **Funding institute:** FDA
- **Fiscal year:** 2020
- **Award amount:** $149,005
- **Award type:** 1
- **Project period:** 2020-04-10 → 2025-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10087166

## Citation

> US National Institutes of Health, RePORTER application 10087166, The Heart Failure Collaboratory Public-Private Partnership Between the United States Food and Drug Administration, the Inova Heart and Vascular Institute, and the Heart Failure Community (1R18FD006920-01). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10087166. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*